They have increased neoantigen expression, increased tumour infiltrating lymphocytes (TILs), and increased expression of programmed death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) in TILs and tumour cells, indicating heightened adaptive immune resistance, which could be targeted by immune checkpoint inhibitor therapy [29]. This evidence concerns the gene CD274 and neoplasm.